retatrutide triple agonist glp-1 gip glucagon 40mg Retatrutide Obesity Triple Agonist Targeting

Plasma peptide concentrations for each blood compartment and time point in the experiment were measured using commercial ELISA kits (for exendin-4: Creative Diagnostics Exendin-4 ELISA kit (cat

When your digestive system is working harder to process food through a slower system, more energy gets directed to digestion, which can contribute to the fatigue some people experience on GLP-1 medications

Other potential risks include pancreatitis, gallbladder disease, diabetic retinopathy complications (with semaglutide), and acute kidney injury if dehydration occurs

Clinical studies have shown that both medications can result in significant weight loss for individuals with type 2 diabetes

Use of GLP-1 RAs was associated with an increased incidence of DR (hazard ratio [HR], 1.07

DPP-4 inhibitors are body weight neutral and they have demonstrated cardiovascular safety